Clinical Trial Update: Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract [Phase 2]

View source ↗

Summary

Phase 2 trial of Nitrocamptothecin for metastatic cancer of the urinary tract has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Transitional Cell Carcinoma of the Renal Pelvis and Ureter
• Urethral Cancer

Drugs mentioned

• Nitrocamptothecin (nitrocamptothecin)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: COMPLETED